Sat, Sep 20, 2014, 11:46 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • golongin2008 golongin2008 Jun 28, 2013 2:32 PM Flag

    CEMP v TSRX

    Very long TSRX but have been reading up on CEMP. Looks like they're competing in the same space and CEMP is behind us, but is their antibiotic any good? Sounds like it has been around for awhile in Europe.
    Productive factual comments either pro or con would be appreciated.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They have two;
      1.solithromycin works on gonorrhea, chlamydia as well as CABP but as U point out your liver may suffer later and at the cost of not having any more slushy drinks.
      2.TAKSTA(phaseII) resistance is noted when used in less potent initial doses. Toxicity in greater doses may limit its efficacy & it's combo applications
      These are both fusidic acid based and are bacteriostatic which limit bacterial growth and
      would have greater resistance tendency unlike bactericidals like TED which kill bacteria. Big difference.

      • 1 Reply to beavertail_splash
      • em438@rocketmail.com em438 Jun 29, 2013 5:07 AM Flag

        Solithromycin is basically a Ketek (tolithromycin) analog by which the pyridine ring was exchanged for an aniline...Yikes! and we all know how well Ketek treated the liver. For the sake of treating deadly infections i hope Solithromycin works and doesn't cause the liver to explode. I just just want to see the AST and ALT numbers...if there is even a hint of elevated liver enzymes in phase 2 then phase 3 we should see more and then general population use will see alot more and even deaths. Still, Solithromycin deserves a chance but at the end of the day TZD is still the top choice.

        As for Fusidic acid, at best, it could be used at a last resort. fusidic acid is already known to have liver tox. and at the massive doses required to be effective this situation will not be made easier.

        Having said all of this, I wouldn't be surprised to see Cemp at 15 to 16 bucks within the year.

    • olafbenson11@gmail.com olafbenson11 Jun 28, 2013 3:21 PM Flag

      And....GAIN act ratified.

    • olafbenson11@gmail.com olafbenson11 Jun 28, 2013 3:21 PM Flag

      Man, TSRX already got the pills out man! Better than Zyvox the market leader, less side effects, less dosage, less duration, better effectiveness, better with other drug combos. This is the easiest play I have seen in a long time. I only wish I knew about this when it was at 5.

    • I believe there are problems with both of CEMP's drugs, one has been around for quite awhile in other countries, the other has been linked to liver problems.

      TSRX is far safer and they own Europe as well as the US market and are further along. From nothing more than an investment standpoint, TSRX is a better investment currently.

 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AutoZone, Inc.
NYSEFri, Sep 19, 2014 4:02 PM EDT
Dresser-Rand Group Inc.
NYSEFri, Sep 19, 2014 4:04 PM EDT